Literature DB >> 31737310

Risk factors of severe hemoptysis in patients with fungus ball.

Tae Hoon Kim1, Hyun Jung Koo2, Chae-Man Lim3, Sang-Bum Hong3, Jin Won Huh3, Kyung Wook Jo3, Tae Sun Shim3, Woo Sung Kim3, Younsuck Koh3.   

Abstract

BACKGROUND: Hemoptysis is one of the most important complications associated with fungus ball. However, the association of the primary size of the fungus ball and its change with the incidence of hemoptysis was not fully established. This study aims to determine the clinical risk factors of severe hemoptysis and natural course of fungus ball.
METHODS: A retrospective study on patients with fungus ball was performed. Patients with severe hemoptysis-related events were compared to those without events, and the predictors for severe hemoptysis were investigated by Cox regression analysis. Three subgroups (decreased, stable, and increased) were classified according to the long-term size change, and the severe hemoptysis-free survival duration was analyzed by the Kaplan-Meier survival curve.
RESULTS: Among 173 patients, 50 (28.9%) experienced severe hemoptysis-related events. Risk-adjusted analysis revealed that age [hazard ratio (HR), 0.964; 95% confidence interval (CI), 0.939-0.989], blood-tinged sputum [HR, 2.717; 95% CI, 1.513-4.879], and thick wall cavitary fungus balls [HR, 2.332; 95% CI, 1.290-4.215] were significant predictors of severe hemoptysis-related events in patients with fungus ball. However, the baseline size of the fungus ball and its change rate were not independent risk factors for severe hemoptysis-related events. Besides, the decreased group did not have a favorable outcome in severe hemoptysis related to fungus ball.
CONCLUSIONS: In a tertiary hospital, the incidence of severe hemoptysis-related events in patients with fungus ball was not low and reached 28.9%. Young patients, those with thick wall cavitary fungus ball, and those with complaints of blood-tinged sputum should be considered for early surgical treatment to prevent severe hemoptysis. 2019 Journal of Thoracic Disease. All rights reserved.

Entities:  

Keywords:  Fungus ball; aspergilloma; hemoptysis; outcome; surgery

Year:  2019        PMID: 31737310      PMCID: PMC6837970          DOI: 10.21037/jtd.2019.09.52

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  31 in total

1.  Haemoptysis due to chronic tuberculosis vs. bronchiectasis: comparison of long-term outcome of arterial embolisation.

Authors:  J-H Lee; S-Y Kwon; H-I Yoon; C J Yoon; K-W Lee; S-G Kang; C-T Lee
Journal:  Int J Tuberc Lung Dis       Date:  2007-07       Impact factor: 2.373

2.  Clinical evaluation of 61 patients with pulmonary aspergilloma.

Authors:  S Kawamura; S Maesaki; K Tomono; T Tashiro; S Kohno
Journal:  Intern Med       Date:  2000-03       Impact factor: 1.271

3.  Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients.

Authors:  Juliette Camuset; Hilario Nunes; Marie-Christine Dombret; Anne Bergeron; Priscilla Henno; Bruno Philippe; Gaelle Dauriat; Gilles Mangiapan; Antoine Rabbat; Jacques Cadranel
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

4.  Clinical profile and surgical outcome for pulmonary aspergilloma: a single center experience.

Authors:  Jayesh Gopal Akbari; Praveen Kerala Varma; Praveen Kumar Neema; Madathipatt Unnikrishnan Menon; Kurur Sankaran Neelakandhan
Journal:  Ann Thorac Surg       Date:  2005-09       Impact factor: 4.330

5.  Surgical management of pulmonary aspergilloma: clinical experience with 77 cases.

Authors:  Koray Aydoğdu; Funda İncekara; Mehmet Furkan Şahin; Selim Şakir Erkmen Gülhan; Göktürk Findik; İrfan Taştepe; Sadi Kaya
Journal:  Turk J Med Sci       Date:  2015       Impact factor: 0.973

6.  Surgical management of symptomatic pulmonary aspergilloma.

Authors:  J W Battaglini; G F Murray; B A Keagy; P J Starek; B R Wilcox
Journal:  Ann Thorac Surg       Date:  1985-06       Impact factor: 4.330

7.  Hemoptysis: a retrospective analysis of 108 cases.

Authors:  A Fidan; S Ozdoğan; O Oruç; B Salepçi; Z Ocal; B Cağlayan
Journal:  Respir Med       Date:  2002-09       Impact factor: 3.415

Review 8.  Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature.

Authors:  Ritesh Agarwal; Gella Vishwanath; Ashutosh N Aggarwal; Mandeep Garg; Dheeraj Gupta; Arunaloke Chakrabarti
Journal:  Mycoses       Date:  2013-03-18       Impact factor: 4.377

9.  Surgical therapy of pulmonary aspergillomas: a 30-year North American experience.

Authors:  Ashok Muniappan; Luis F Tapias; Parag Butala; John C Wain; Cameron D Wright; Dean M Donahue; Henning A Gaissert; Michael Lanuti; Douglas J Mathisen
Journal:  Ann Thorac Surg       Date:  2013-12-21       Impact factor: 4.330

10.  Analysis of patients with hemoptysis in a tertiary referral hospital.

Authors:  Bo Ram Lee; Jin Yeong Yu; Hee Jung Ban; In Jae Oh; Kyu Sik Kim; Yong Soo Kwon; Yu Il Kim; Young Chul Kim; Sung Chul Lim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-08-31
View more
  1 in total

1.  Stereotactic body radiotherapy for recurrent hemoptysis due to chronic pulmonary aspergillosis: a case report and systematic review of the literature.

Authors:  Alexander Koch; Daniel H Schanne; Gunar Günther; Daniel M Aebersold; Olgun Elicin
Journal:  Strahlenther Onkol       Date:  2022-10-20       Impact factor: 4.033

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.